Cargando…
Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer
SIMPLE SUMMARY: Inhibition of MEK has been proposed as a means to address mutant RAS colorectal cancer (CRC). However, MEK inhibitor adaptive resistance has led to reduced clinical utility of this new drug. Our studies have suggested the potential for the addition of an SRC inhibitor to prevent the...
Autores principales: | Davis, Thomas Benjamin, Gupta, Shilpa, Yang, Mingli, Pflieger, Lance, Rajan, Malini, Wang, Heiman, Thota, Ramya, Yeatman, Timothy J., Pledger, Warren Jackson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945886/ https://www.ncbi.nlm.nih.gov/pubmed/35326598 http://dx.doi.org/10.3390/cancers14061451 |
Ejemplares similares
-
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Thota, Ramya, et al.
Publicado: (2021) -
Spatiotemporal trends in mean and extreme climate variables over 1981–2020 in Meki watershed of central rift valley basin, Ethiopia
por: Terefe, Simret, et al.
Publicado: (2022) -
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
por: Yang, Mingli, et al.
Publicado: (2022) -
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022) -
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
por: Rogala, Paweł, et al.
Publicado: (2022)